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Objective: Carriers of a functional mutation in LCAT, encoding lecithin:cholesterol acyl transferase, are
exposed to lifelong low high-density lipoprotein cholesterol (HDL-c) levels. We investigated whether
LCAT mutation carriers have increased arterial stiffness as a marker of cardiovascular disease and
whether arterial stiffness was associated with carotid wall thickening.
Methods: We assessed 45 carriers of LCAT mutations (mean age  SD 46  13 yrs) and 45 age-matched
controls. Probands referred with established cardiovascular disease were excluded. We measured
carotid-fermoral pulse wave velocity (PWV) and carotid artery wall thickening by ultrasound and 3.0 T
magnetic resonance imaging.
Results: In carriers, HDL-c was lower (32  12 vs. 59  16 mg/dl; p < 0.0001) and triglycerides were
higher (median 116 [IQR 80e170] vs. 71 [IQR 53e89] mg/dl; p < 0.001) vs. controls. PWV was higher in
carriers vs. controls (7.9  2.0 m/s vs. 7.1  1.6 m/s; p < 0.01). This difference retained signiﬁcance in
multivariate analysis including age, sex, mean arterial pressure and body mass index, and after exclusion
of carriers and controls with cardiovascular disease. Both in carriers and controls, PWV was correlated
with wall thickening of the carotid arteries as assessed by ultrasound (R 0.50, p < 0.001 for carriers and
R 0.36, p < 0.04 for controls) and 3.0 T magnetic resonance imaging (R 0.54, p < 0.001 for carriers and
R 0.58, p < 0.001 for controls).
Conclusion: Pulse wave velocity is increased in LCAT mutation carriers with low HDL-c and is associated
with carotid wall thickening.
 2012 Elsevier Ireland Ltd. Open access under the Elsevier OA license.1. Introduction
A low plasma level of high-density lipoprotein cholesterol (HDL-
c) is a strong and independent predictor of cardiovascular disease
(CVD) [1,2]. Carriers of mutations in LCAT, encoding lec-
ithin:cholesterol acyl transferase, are exposed to lifelong lowHDL-c
levels. LCAT is a crucial enzyme in HDL metabolism produced in the
liver and small intestine [3,4]. Upon secretion into the circulation, it
associates predominantly with HDL where it esteriﬁes free
cholesterol using apolipoprotein A-I (apoA-I) as a cofactor [4].Medicine, Academic Medical
f 9, 1105 AZ Amsterdam, The
9343.
den Bogaard).
der the Elsevier OA license.Carriers of LCAT mutations have been reported to suffer from
increased atherosclerosis, but this is disputed. In this respect, two
ultrasound studies reached opposite conclusions, one study
reporting increased intima media thickness (IMT) in the carotid
arteries of carriers as a surrogate outcome for atherosclerosis [5]
and the other reporting decreased IMT in carotid arteries of
carriers compared controls [6]. We have recently conﬁrmed the
ﬁndings of our earlier study by showing structural abnormalities in
the carotid arteries of LCAT mutation carriers with low HDL-c
compared to matched controls using both ultrasound and 3.0 T
magnetic resonance imaging of the carotid arteries [7]. Whether
the observed atherosclerotic structural changes in LCAT mutation
carriers are associatedwith functional alterations of large arteries is
undetermined. Arterial stiffness is a strong and independent
predictor of cardiovascular disease (CVD) [8e10]. Pulse wave
velocity (PWV), the gold standard of non-invasive measurement of
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dicting cardiovascular mortality and morbidity.
We hypothesized that patients with LCAT gene mutations, with
lifelong exposure to lowHDL-c levels, would have increased arterial
stiffness compared to healthy controls. We therefore studied
carotid-femoral PWV, in patients with LCAT gene mutations and
age-matched controls. In addition to our primary study objective,
we also examined the association between arterial stiffness and
structural changes in large arteries by assessment of wall thick-
ening of the carotid arteries using B-mode ultrasound (intima
media thickness [IMT]) and 3.0 T magnetic resonance imaging
(MRI).
2. Methods
2.1. Study design and participants
The design of this study has been described in detail [7]. In brief,
the study was conducted at the Academic Medical Center in
Amsterdam, The Netherlands from October 2008 to October 2009.
The study protocol was approved by the local institutional review
board and all subjects provided written informed consent. Patients
molecularly diagnosed with LCAT mutations were enrolled in this
study, irrespective of their age and sex. In order to limit referral
bias, we excluded family probands who were referred to our
outpatient clinic with clinically manifest CVD. For the control
group, unaffected family members of the included carriers were
asked to participate in the study, comprising ﬁrst, second or third
degree family members or spouses. These controls were included if
they could be individually matched for age to carriers. Because the
number of family controls was insufﬁcient the control group was
complementedwith unrelated controls recruited by advertisement.
Family history of CVD, presence of cardiovascular risk factors, use of
medication and alcohol were assessed. Presence of hypertension
was deﬁned as a systolic blood pressure (SBP) > 140 mmHg,
a diastolic blood pressure (DBP) > 90 mmHg or use of antihyper-
tensive medication.
2.2. Blood pressure and arterial stiffness
Participants visited the hospital after an overnight fast and
were asked to refrain from smoking (if applicable) at least 3 h
before the visit. All measurements were carried out in supine
position after 15 min rest in a quiet, temperature-controlled room.
All hemodynamic measurements were performed by a single
investigator (BvdB) who was blinded for the genetic status of the
participants. Brachial blood pressure was measured 3 times at 1-
min intervals in supine position at the right arm after 15 min
rest using a validated oscillometric device (Omron 705IT). The
mean of the last 2 measurements was used for analysis.
Measurements of carotid-femoral pulse wave velocity (PWV) were
performed with the SphygmoCor system (Atcor Medical Pty Ltd,
West Ryde, Australia). Pulse waveforms were recorded at the right
carotid and femoral artery sequentially. Wave travel distance was
calculated by subtracting carotid artery e suprasternal notch
distance from suprasternal notch e femoral artery distance.
Measurements were conducted in duplicate and means were used
for analysis.
2.3. Carotid ultrasound and magnetic resonance imaging
Ultrasound scans of the carotid arterial wall were assessed as
surrogate outcome for atherosclerosis according to a standardized
protocol [12]. Values given are means of left and right common
carotid artery, carotid bulb and internal carotid. Bilateral 3.0 T MRIscans of the carotid arteries were obtained as previously described
[7]. Normalized wall index (NWI) represents mean vessel wall area
normalized for the transverse size of the vessel, measured as the
outer wall area. Carotid IMT and NWI were assessed during the
same hospital visit as PWV.
2.4. Plasma lipids
Blood was obtained after overnight fasting and stored using
standardized protocols. Plasma total cholesterol, HDL-c and
triglyceride levels were analyzed using a commercially available
enzymatic method (Westburg, USA) on a Cobas Mira autoanalyzer
(Roche, Switzerland). Low density lipoprotein cholesterol (LDL-c)
levels were calculated using the Friedewald equation. Non-HDL-c is
total cholesterol e HDL-c.
2.5. Statistical analysis
Data are expressed as means  standard deviations (SD),
median (interquartile range [IQR]) or numbers and percentages
where appropriate. Differences between carriers and controls were
assessed by comparison of continuous data using independent t-
tests for parametric data and ManneWhitney for non-parametric
data; chi-square test was applied to compare categorical data.
Correlations are expressed as Pearson’s correlation coefﬁcient. A
multivariate model was used with generalized estimating equa-
tions in the SAS procedure GENMOD to account for potential
confounders, i.e. age, gender, mean arterial pressure (MAP), pres-
ence of hypertension, non-HDL-c, body mass index (BMI) and
correlations within families due to clustering of genetic and/or
environmental factors, using stepwise backward elimination.
Statistical analyses were done using SPSS (Statistical Package for
the Social Sciences) version 16.0 and SAS package version 9.1 (SAS
Institute Inc., Cary, NC USA). The authors had full access to the raw
data and take responsibility for its integrity.
3. Results
3.1. Population characteristics
We studied 45 carriers of LCAT gene mutations from 15 families,
all of Dutch descent, and 45 age-matched controls of which 19were
family members and 26 were unrelated individuals. Of the carriers,
43 had one mutant LCAT allele, while 1 was homozygous for T147I
and one was compound heterozygous for T147I and V333M. Both
the homozygote and the compound heterozygote had previously
presented with corneal opaciﬁcation and HDL deﬁciency, without
the presence of proteinuria, and had thus been diagnosed with ﬁsh
eye disease (FED).
Table 1 summarizes the demographic, lifestyle, and clinical
characteristics of carriers and controls. Propermatching for agewas
achieved for carriers of an LCAT mutation and controls. The
percentage of males did not differ between the two groups. On
average, carriers had a 1.9 kg/m2 higher BMI (p ¼ 0.02). More
carriers had experienced cardiovascular events and received statin
treatment than controls, and carriers tended to receive antihyper-
tensive treatment more frequently than controls. Mean blood
pressurewas 13515/79 9mmHg for LCATmutation carriers and
13113/77 9mmHg for controls (p¼ 0.12/p¼ 0.19). HDL-c levels
in carriers of LCAT mutations were lower compared to controls
(32  12 vs. 59  16 mg/dl, p < 0.001), while LDL-c levels were
identical (125  35 mg/dl for LCAT carriers and 125  31 mg/dl for
controls, p ¼ 0.65). Triglycerides were higher in carriers of LCAT
mutations: 116 [IQR 80e170] mg/dl compared to 71 [IQR 53e89]
mg/dl in controls (p < 0.001).
Table 1
Clinical characteristics of LCAT mutation carriers compared to unaffected controls.
LCAT mutation
carriers
Matched
controls
p
n 45 45
Age, years 46  13 45  14 0.83
Male sex, n (%) 35 (78%) 29 (64%) 0.16
BMI, kg/m2 26.3  4.1 24.6  3.0 0.02
Smoking, n (%) 7 (16%) 5 (11%) 0.54
History of CVD, n (%) 6 (13%) 1 (2%) 0.05
Hypertension, n (%) 17 (38%) 13 (29%) 0.37
SBP, mmHg 135  15 131  13 0.12
DBP, mmHg 79  9 77  9 0.19
Statin users, n (%) 16 (36%) 1 (2%) <0.001
Total cholesterol, mg/dl 172  47 191  35 0.05
LDL-c, mg/dl 125  35 125  35 0.75
HDL-c, mg/dl 32  12 59  16 <0.001
Non-HDL-c, mg/dl 140  41 131  35 0.31
Triglycerides, mg/dl 116 [IQR 80e170] 71 [IQR 53e89] <0.001
Diabetes mellitus, n 0 0 e
Values are indicated as means  SD or median [IQR] unless otherwise indicated.
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matched controls
PWV was higher in carriers of a mutation in LCAT compared to
controls, 7.9  2.0 vs. 7.1  1.6 m/s (p < 0.01), see Fig. 1. In
a multivariate regression model that adjusted for age, sex, MAP,
hypertension, non-HDL-c, BMI and family clustering, this difference
retained statistical signiﬁcance (p < 0.01). After exclusion of
matched pairs of which the carrier (n ¼ 6) and/or control (n ¼ 1)
had suffered from CVD, the PWV of the 38 remaining carriers
remained signiﬁcantly higher compared to the respective matched
controls (7.7 2.0 and 6.9 1.6m/s, p< 0.05). Again, this differenceFig. 1. Carotid-femoral pulse wave velocity in carriers of an LCAT mutation and
matched controls. Boxed values are means  SD for PWV. *Difference retained
signiﬁcance in multivariate analysis, independent of age, sex, mean arterial pressure,
hypertension, non-HDL-cholesterol, BMI and correlations within families due to
clustering of genetic and/or environmental factors, and also after exclusion of 6
matched pairs with members with a history of CVD.retained signiﬁcance after adjustment for age, sex, MAP and family
clustering in themultivariate regressionmodel (p< 0.01). PWVwas
not correlated with HDL-c in the whole study group (R ¼ 0.11,
p ¼ 0.32), in LCAT mutation carriers (R ¼ 0.05, p ¼ 0.75) or in
controls (R ¼ 0.13, p ¼ 0.41).
3.3. PWV and carotid wall thickening assessed by ultrasound and
3.0 T MRI
In a random set of 36 carriers and 36 controls individually
matched for age, carotid wall thickening was assessed by ultra-
sound (cIMT) and by 3.0 T MRI scanning [7]. Table 2 and Fig. 2 show
that PWV correlated well with both cIMT and carotid NWI obtained
by MRI. Within the carrier group, stepwise backward elimination
with the GenMod procedure accounting for family relations
revealed that age and gender were the most powerful predictors of
cIMT, while NWI was best predicted by age, gender and non-HDL-c.
The strongest predictors of PWV were age and MAP. Stepwise
backward elimination in controls yielded the same predictors for
cIMT, NWI and PWV.
4. Discussion
In this study we show that aortic pulse wave velocity is
increased in LCAT mutation carriers compared to controls, indica-
tive of increased arterial stiffness in these patients. This difference
retained signiﬁcance in multivariate analysis and after exclusion of
patients with CVD. In addition to our primary study objective, this
study also reveals a strong correlation between arterial stiffness
and thickness of the carotid arterial wall as assessed by ultrasound
(IMT) and 3.0 T MRI.
4.1. Arterial stiffness in LCAT deﬁciency
The observed increase in arterial stiffness in LCAT mutation
carriers might result from accelerated atherosclerosis in these
patients, which in turn might be caused by decreased reverse
cholesterol transport from the vascular wall due to the impaired
maturation of HDL-c. We did, however, not observe a correlation of
PWV with HDL-c (not in carriers, nor in controls), although this
might be explained by large standard deviations in both parameters
and small group size. Supporting our observations of increased PWV
inpersons exposed to lifelong lowHDL-c levels, PWVwaspreviously
found to be inversely related to HDL-c levels [13e15]. In a pop-
ulation-based study, 122 middle-aged subjects with low HDL-c
levels had signiﬁcantly higher PWV independent of age, sex, phys-
ical activity and smoking status, compared to 795 subjects with
normal HDL-c levels [13]. In a cross-sectional study among post-
menopausal women, HDL-c was also reported to be inversely and
independently related to PWV [14]. However, in two of these studies
no adjustment was made for blood pressure, an important deter-
minant of PWV [16]. In our study, LCAT mutation carriers with lowTable 2
Correlations of carotid-femoral pulse wave velocity with normalized wall index
(MRI) and carotid intimamedia thickness (ultrasound) in LCATmutation carriers and
controls.
Normalized wall
index (MRI)
Carotid IMT
(ultrasound)
PWV LCAT mutation carriers (n ¼ 36)a 0.54 (p < 0.001) 0.50 (p < 0.001)
PWV matched controls (n ¼ 36)a 0.58 (p < 0.001) 0.36 (p ¼ 0.04)
Values are Pearson’s correlation coefﬁcients R, with respective p-values in brackets.
a For 9 of 45 matched controls in which PWV was assessed, no MRI or ultrasound
data were available. Respective matched carriers were excluded from correlation
analysis, rendering 36 matched pairs.
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Fig. 2. Scatter plot of PWV to IMT (carotid ultrasound) and NWI (carotid MRI). a:
Carotid-femoral PWV plotted to carotid IMT. Continuous line indicates correlation
between PWV and cIMT in controls (open symbols; n ¼ 36), Pearson’s R ¼ 0.36
(p ¼ 0.04); Dashed line indicates correlation between PWV and cIMT in LCAT mutation
carriers (closed symbols; n ¼ 36), Pearson’s R ¼ 0.50 (p < 0.001). b: Carotid-femoral
PWV plotted to carotid NWI, assessed by 3.0 T MRI. Continuous line indicates corre-
lation between PWV and NWI in controls (open symbols; n ¼ 36), Pearson’s R ¼ 0.58
(p < 0.001); Dashed line indicates correlation between PWV and NWI in LCATmutation
carriers (closed symbols; n ¼ 36), Pearson’s R ¼ 0.54 (p < 0.001).
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blood pressure.
We identiﬁed a slight increase in BMI in carriers. However in
multivariate analysis, BMI did not affect the relation between LCAT
genotype and PWV. This is in accordance with a systematic review,
indicating that risk factors other than age and blood pressure
contribute only modestly to arterial stiffness [16].
We can only speculate whether increasing HDL-c in LCAT
mutation carriers would lead to reversal of increased arterial
stiffness. In carriers of ABCA1 mutations, who also suffer from low
HDL-c levels, endothelial function of the brachial artery as assessed
by ﬂow mediated dilation was reduced and infusion of recon-
stituted HDL (rHDL) restored endothelial function in these patients
[17]. It would be of interest to see whether therapy aimed at
limiting the progression of atherosclerosis in these extreme
atherogenic phenotypes may also improve arterial stiffness.4.2. Correlation of arterial stiffness to carotid wall thickening
We observed a strong correlation between arterial stiffness and
carotid wall thickness both by carotid ultrasound and MRI. This is in
linewith previous observations showing that PWV is associatedwithc-IMT in the general population [9], hypertensive patients [18], and in
patients with type 2 diabetes mellitus [19]. However, there is
discussion about the nature of the association between arterial
stiffness and atherosclerosis [20]. Although it has been speculated
that arterial stiffnessmight simply reﬂect the atherosclerotic burden,
the relationship might be causal: arterial stiffness may promote
atherosclerosis by causing increased wave reﬂections leading to
elevated pulse pressurewhich increases shear stress andmay lead to
the formationof atherosclerotic plaques. The strong relationbetween
PWV and arterial wall thickness in our study underscores the inter-
relation between arterial stiffness and arterial wall thickening and
fuels the discussion about the role of arterial stiffness in atherogen-
esis. The observation that the same set of predictors were associated
with cIMT, NWI and PWV in LCAT mutation carriers and controls
suggests that the atherosclerotic process resulting in increased arte-
rial stiffening observed in LCAT mutation carriers is subject to the
same well known factors as found in unaffected subjects. Large
prospective studies should further address the nature of the relation
between arterial stiffness and atherosclerosis.
4.3. Strengths and weaknesses
Several aspects of our study merit closer consideration. An
important strength of our study is that LCATmutation carriers were
individually matched with controls and that LCATmutation carriers
who were referred to our outpatient clinic with a history of CVD
were excluded tominimize potential referral bias.We only included
carriers identiﬁed in families of which the probands were asymp-
tomatic for cardiovascular disease. Furthermore, the use of statins
and antihypertensive medication is considerably higher in LCAT
mutation carriers, and since both statins [21,22] and antihyperten-
sive drugs [23] have shown to decrease PWV, the actual difference in
PWVmight even be larger between carriers and controls.
Our study has the following limitations. First, compared to
controls, carriers show increased levels of plasma triglycerides,
a ﬁnding that has also been reported by others [24] and which is
possibly caused by increased de novo lipogenesis in the liver [25].
However, in a recent population-based study, PWV was not asso-
ciatedwith triglycerides [15], making it unlikely that the increase in
triglycerides contributes to the increased PWV in carriers. Secondly,
since carriers had a higher BMI it is possible they might have lower
levels of physical activity and higher fat intake. We did not assess
this and therefore have not corrected for physical activity or diet.
Third, it remains unclear whether carriers of LCAT mutations have
an increased cardiovascular risk. Since low HDL-c caused by LCAT
deﬁciency is a rare condition, we have no data on the prevalence of
cardiovascular disease in LCAT mutation carriers. However, we
previously showed that carotid wall thickness measured with MRI
and ultrasound is enhanced compared to controls suggesting
accelerated atherosclerosis [7]. Contrary to our previous report,
Calabresi et al. have shown a decreased carotid wall thickness in
LCAT mutation carriers [6,7]. These seemingly conﬂicting results
might be explained by differences in gene mutations. Most of the
carriers of LCAT gene mutations have loss of a-activity, which is
LCAT activity on HDL, whereas the majority of subjects in the study
of Calabresi et al. exhibited loss of function mutations of a- and b-
activity, which corresponds to LCAT activity on HDL and LDL.
Accordingly, LDL-c levels in our previous study and present report
were higher compared to those in Calabresi’s study.
4.4. Perspectives
Since carriers of LCATmutations characterizedby lowHDL-c levels
have increased arterial stiffness compared to unaffected controls, we
consider that this study supports close clinical monitoring of
B. van den Bogaard et al. / Atherosclerosis 225 (2012) 481e485 485cardiovascular risk factors incarriersofLCATmutations. BecausePWV
is a reproducible, non-invasive and readily applicable functional
measure of arterial stiffness, it may be a useful method to assess and
monitor the increased CVD risk in these patients.
In addition to statins and antihypertensive medication,
increasing HDL-c through lifestyle modiﬁcations or pharmacolog-
ical treatment might also reduce arterial stiffness by improvement
of cholesterol efﬂux, reduction of inﬂammation or improvement of
endothelial function [13,26,27]. In future studies, it would be of
interest to examine whether treatment speciﬁcally aimed at
increasing HDL-c will affect arterial stiffness. Also, our data bolster
the notion that LCAT might be an interesting target to reduce
cardiovascular risk and support LCATenhancing strategies currently
evaluated in preclinical studies [28,29].
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